You notice something on your skin. A patch. A mark. A spot that wasn't there before, or that's been there so long you've stopped thinking about where it came from. You search "hyperpigmentation" and get a wall of results that seem to be talking about different things simultaneously.
That's because they are. Hyperpigmentation is an umbrella term. It describes any darkening of skin caused by excess melanin production. Under that umbrella live four meaningfully different presentations that look similar at a glance and need different approaches to address.
Here's how to tell them apart.
Melanocytes (the cells that produce melanin) respond to triggers by producing more pigment than the surrounding skin. That excess pigment shows up as darker skin. The trigger varies: UV radiation, inflammation, hormones, physical injury. The mechanism is always excess melanin. But the cause changes everything about what you're looking at and what will actually help.
The origin: PIH follows inflammation or injury. Acne, eczema, a cut, a burn, aggressive skincare, or friction triggers a healing response in which melanocytes overproduce melanin in the affected area.
What it looks like: PIH follows the exact shape and size of whatever caused it. A pimple leaves a pimple-shaped mark. An eczema patch leaves a patch-shaped darkening. Borders are defined. Color ranges from light brown to deep black or purple depending on skin tone and how deep the pigmentation sits.
Where: Wherever inflammation occurred (face, body, literally anywhere).
How it behaves: Fades gradually without treatment (2-4 months for surface pigmentation, up to 12 months for deeper). Doesn't fluctuate seasonally. More visible and more persistent in melanin-rich skin because melanocytes are more reactive.
The origin: Melasma is driven by hormones and amplified by UV exposure. Pregnancy, hormonal contraceptives, and perimenopause are the most common triggers. The hormonal signal causes melanocytes in specific areas to become chronically overactive.
What it looks like: Broad, diffused patches in brown or grey-brown with soft, smudged edges rather than defined borders. Almost always bilateral: it appears symmetrically on both sides of the face. Cheeks, forehead, upper lip, and nose bridge are the most common sites.
Where: Almost exclusively the face.
How it behaves: Melasma fluctuates. It darkens with UV exposure and hormonal shifts, and may fade in winter. It is the most persistent and most likely to return after treatment because the triggers are ongoing. Managing melasma is a long-term practice, not a course of treatment.
The origin: Cumulative UV exposure over years triggers localized, permanent increases in melanocyte activity. They are not a response to a single event. They accumulate over time.
What it looks like: Small to medium, flat, well-defined spots in light to medium brown on areas with chronic sun exposure. Clear borders, consistent color within each spot, stable appearance year-round.
Where: Face (particularly temples, cheekbones, nose), back of hands, forearms, shoulders, décolletage.
How it behaves: Stable and consistent, unlike melasma, they don't significantly fluctuate. They accumulate more with continued UV exposure and fade slowly with treatment and sun protection.
The origin: Genetic. Freckles reflect the natural distribution pattern of melanocytes in certain skin types, predominantly fair or red-haired people with Fitzpatrick types I-III.
What it looks like: Small, scattered, light brown spots. Multiple across an area rather than isolated.
Where: UV-exposed areas, particularly the nose, cheeks, and shoulders.
How it behaves: Darken with UV exposure and fade in winter. This seasonal fluctuation is the clearest distinguishing feature from sun spots, which are stable year-round.
Where did it start? PIH can be traced to a specific wound or breakout. Melasma spreads in patterns without a preceding injury. Sun spots accumulate on UV-exposed areas over years.
Does it fluctuate? Melasma worsens with sun and hormones and may fade in winter. Freckles darken and fade seasonally. PIH and sun spots are relatively stable once formed.
What are the edges like? Melasma has soft, blurred edges. PIH and sun spots have defined borders.
If still unclear (particularly for melasma vs. other forms), a dermatologist can use a Wood's lamp to distinguish epidermal from dermal pigmentation, which directly affects which treatment approach will work.
Most effective approaches work by interrupting melanin synthesis through the tyrosinase enzyme. Different ingredients inhibit it through different pathways, which is why multi-pathway approaches outperform single-ingredient ones, and why sunscreen is the non-negotiable foundation for any type.
For all types: Daily broad-spectrum SPF. UV exposure worsens every form of hyperpigmentation and directly reverses the progress of any treatment ingredient.
For PIH: Niacinamide (prevents melanin transfer), tyrosinase inhibitors (oxyresveratrol, glabridin, arbutin), gentle exfoliation to support surface turnover.
For melasma: Consistent sun protection is the primary intervention. Azelaic acid and niacinamide are better tolerated than stronger actives, which can irritate and worsen melasma. Hydroquinone under dermatologist supervision for persistent cases.
For sun spots: Retinoids and AHAs (accelerate turnover), tyrosinase inhibitors, and consistent SPF to prevent new formation alongside treatment of existing spots.
For freckles: The framing question is whether treatment is the goal. Freckles are genetic and reflect how your skin responds to UV. If fading them matters, tyrosinase inhibitors and consistent SPF help, but with seasonal fluctuation, some return is expected.
Hyperpigmentation is not one thing, and treating it as one thing is why the category is so consistently frustrating. The same serum that addresses PIH may not address melasma. The approach that works for sun spots may not suit reactive skin managing acne-related marks.
Identify the type first. Address the trigger. Then choose ingredients that work on the specific pathway driving what you're seeing.
Written by Devanshi Garg, Founder of Motif Skincare. The Motif editorial process is informed by ongoing collaboration with our Chief Dermatology Advisor, Dr. Indy Chabra, MD, board-certified dermatologist with a Ph.D. in Microbiology and Genetics. This article is for educational purposes only and does not constitute medical advice.
Last reviewed: 10th July, 2026.
